EXAS

EXAS is effectively 'pinned' to its acquisition price by Abbott Laboratories (deal announced Nov 2025), which explains the anomalous 2.9% annualized volatility and the 'Quiet Storm' technical signal (misinterpreting a deal peg as a breakout coil). While the 'Caution' macro regime pressures the broader tech/AI sector, EXAS has decoupled as a merger-arbitrage play, trading just 0.1% off its highs in anticipation of the deal closing. The 'Steady Climb' signal reflects the gradual narrowing of the arbitrage spread rather than organic price discovery.